The functionality of Beclin 1 is critical for understanding the mechanisms of cancer development. Research indicates that reduced expression of Beclin 1 is associated with poor prognosis in cancers such as breast cancer, ovarian cancer, and colorectal cancer. Hence, studying Beclin 1 can reveal potential therapeutic targets and biomarkers for these diseases.
